Multiple myeloma is a malignant tumour of plasma cells infiltrating the bone marrow. The median age of presentation of myeloma is 65 years. A high index of suspicion is important for early recognition of the condition, especially to avoid renal failure from setting in as established renal failure can change the overall prognosis in myeloma patients.
This article gives a quick snapshot of when to suspect myeloma in primary care.
Clues from investigations:
Tests to send for diagnosing myeloma (in addition to the above-mentioned):
SingHealth Duke-NUS Blood Cancer Centre (SDBCC) hosts specialty clinics for multiple myeloma, run by Haematologists specially trained to manage such patients. We often have clinical trials for patients with myeloma that help us to bring some of the most effective and newest discovered medicines against myeloma to our patients.
For more information on myeloma, please visit
GPs can call for appointments through the GP Appointment Hotlines at 6321 4402 (SGH) or 6436 8288 (NCCS).
By: Dr Chandramouli Nagarajan, Consultant, Department of Haematology, Singapore General Hospital; SingHealth Duke-NUS Blood Cancer Centre
Dr Chandramouli Nagarajan is a Consultant at the Department of Haematology, Singapore General Hospital (SGH) and the SingHealth Duke-NUS Blood Cancer Centre (SDBCC). He is a Clinical Lecturer at the NUS Yong Loo Lin School of Medicine and an Adjunct Assistant Professor at the Duke-NUS Medical School. He served as a Consultant Haematologist in the Northwest of England for 2½ years before joining SGH in 2014.
His main area of interest is malignant haematology, especially lymphomas, myeloma, as well as immune and laboratory haematology. His other area of interest is clinical/medical education and he has been involved in teaching undergraduate and postgraduate students throughout his career. He has contributed as a member of several committees, was the clinical lead for blood transfusion services and has been involved in research, serving as Principal Investigator in clinical trials, during his tenure in the United Kingdom.
Subscribe to our mailing list to get the updates to your email inbox...